Movatterモバイル変換

[0]ホーム
URL:

IES20140313A2 - An injectable antibody preparation for use in treating or reducing the risk of atopic dermatitis or asthma - Google Patents

An injectable antibody preparation for use in treating or reducing the risk of atopic dermatitis or asthma

Info

Publication number
IES20140313A2
IES20140313A2IES20140313AIES20140313AIES20140313A2IE S20140313 A2IES20140313 A2IE S20140313A2IE S20140313 AIES20140313 AIE S20140313AIE S20140313 AIES20140313 AIE S20140313AIE S20140313 A2IES20140313 A2IE S20140313A2
Authority
IE
Ireland
Prior art keywords
human
antibody
asthma
risk
treating
Prior art date
Application number
IES20140313A
Inventor
Jasper Clube
Original Assignee
Kymab Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US14/472,698external-prioritypatent/US8986694B1/en
Priority claimed from US14/472,685external-prioritypatent/US8992927B1/en
Priority claimed from US14/472,818external-prioritypatent/US8980273B1/en
Priority claimed from US14/472,828external-prioritypatent/US8986691B1/en
Priority claimed from US14/490,160external-prioritypatent/US8999341B1/en
Priority claimed from EP14185297.0Aexternal-prioritypatent/EP2975058A1/en
Priority claimed from US14/490,175external-prioritypatent/US9040052B1/en
Priority claimed from US14/500,233external-prioritypatent/US9045548B1/en
Priority claimed from US14/507,368external-prioritypatent/US9034332B1/en
Priority claimed from US14/536,129external-prioritypatent/US9062105B1/en
Priority claimed from US14/536,049external-prioritypatent/US9045545B1/en
Priority claimed from US14/537,403external-prioritypatent/US9067998B1/en
Application filed by Kymab LtdfiledCriticalKymab Ltd
Publication of IES20140313A2publicationCriticalpatent/IES20140313A2/en
Publication of IES86597B2publicationCriticalpatent/IES86597B2/en

Links

Landscapes

Abstract

An injectable preparation comprising an antibody or antibody fragment for use in a method of treating or reducing the risk of atopic dermatitis or asthma in humans is described. The antibody or antibody fragment of the preparation specifically binds to a human IL4Ra protein that comprises a selected mutation from the group consisting of 175V, E400A, C431R, S503P, Q576R and S752A in SEQ ID NO. 67. The antibody or antibody fragment comprises a human gamma-4 heavy chain constant region that comprises an amino acid selected from the group consisting of a Leu at position 189 shown in SEQ ID NO 73 and an Arg at position 289 shown in SEQ ID NO. 73. The human comprises an IGHG4*01 human heavy chain constant region gene segment, or the human expresses antibodies comprising human gamma-4 heavy chain constant regions comprising said selected amino acid. The human further comprises a nucleotide sequence encoding said IL4Ra protein comprising said selected mutation.
IES20140313A2014-08-292014-12-16An injectable antibody preparation for use in treating or reducing the risk of atopic dermatitis or asthmaIES20140313A2 (en)

Applications Claiming Priority (20)

Application NumberPriority DateFiling DateTitle
US14/472,828US8986691B1 (en)2014-07-152014-08-29Method of treating atopic dermatitis or asthma using antibody to IL4RA
US14/472,685US8992927B1 (en)2014-07-152014-08-29Targeting human NAV1.7 variants for treatment of pain
US14/472,818US8980273B1 (en)2014-07-152014-08-29Method of treating atopic dermatitis or asthma using antibody to IL4RA
US14/472,698US8986694B1 (en)2014-07-152014-08-29Targeting human nav1.7 variants for treatment of pain
US14/490,160US8999341B1 (en)2014-07-152014-09-18Targeting rare human PCSK9 variants for cholesterol treatment
US14/490,112US9034331B1 (en)2014-07-152014-09-18Targeting rare human PCSK9 variants for cholesterol treatment
US14/490,091US9068012B1 (en)2014-07-152014-09-18Targeting rare human PCSK9 variants for cholesterol treatment
US14/490,175US9040052B1 (en)2013-12-172014-09-18Precision Medicine by targeting rare human PCSK9 variants for cholesterol treatment
EP14185297.0AEP2975058A1 (en)2014-07-152014-09-18Antibodies for use in treating conditions related to specific PCSK9 variants in specific patient populations
US14/500,397US10618971B2 (en)2013-12-172014-09-29Targeting rare human PCSK9 variants for cholesterol treatment
US14/500,233US9045548B1 (en)2014-07-152014-09-29Precision Medicine by targeting rare human PCSK9 variants for cholesterol treatment
US14/507,368US9034332B1 (en)2014-07-152014-10-06Precision medicine by targeting rare human PCSK9 variants for cholesterol treatment
EP141909452014-10-29
US14/536,129US9062105B1 (en)2014-07-152014-11-07Precision Medicine by targeting VEGF-A variants for treatment of retinopathy
US14/536,049US9045545B1 (en)2014-07-152014-11-07Precision medicine by targeting PD-L1 variants for treatment of cancer
US14/537,403US9067998B1 (en)2014-07-152014-11-10Targeting PD-1 variants for treatment of cancer
US14/552,816US10611849B2 (en)2013-12-172014-11-25Precision medicine by targeting rare human PCSK9 variants for cholesterol treatment
EP141966412014-12-05
EP141966382014-12-05
EP141966452014-12-05

Publications (2)

Publication NumberPublication Date
IES86597B2 IES86597B2 (en)2015-11-18
IES20140313A2true IES20140313A2 (en)2015-11-18

Family

ID=54365489

Family Applications (2)

Application NumberTitlePriority DateFiling Date
IES20140313AIES20140313A2 (en)2014-08-292014-12-16An injectable antibody preparation for use in treating or reducing the risk of atopic dermatitis or asthma
IES20140312AIES86598B2 (en)2014-08-292014-12-16An injectable antibody preparation for use in treating or reducing the risk of atopic dermatitis or asthma

Family Applications After (1)

Application NumberTitlePriority DateFiling Date
IES20140312AIES86598B2 (en)2014-08-292014-12-16An injectable antibody preparation for use in treating or reducing the risk of atopic dermatitis or asthma

Country Status (1)

CountryLink
IE (2)IES20140313A2 (en)

Also Published As

Publication numberPublication date
IES86597B2 (en)2015-11-18
IES20140312A2 (en)2015-11-18
IES86598B2 (en)2015-11-18

Similar Documents

PublicationPublication DateTitle
EP3991748A3 (en)Anti-sortilin antibodies and methods of use thereof
NZ775762A (en)Anti-tau antibodies and methods of use
NZ711451A (en)Anti-c5 antibodies having improved pharmacokinetics
PH12019500209A1 (en)Methods and compositions for gene expression in plants
MY188761A (en)Method of reducing serum levels of fc-containing agents using fcrn antagonists
WO2017062672A3 (en)Anti-trem2 antibodies and methods of use thereof
NZ630610A (en)Tau peptides, anti-tau antibodies, and methods of use thereof
PH12018501282A1 (en)Anti-c5 antibodies and methods of use
MY198942A (en)Anti-tau antibodies and methods of use
PH12017501114B1 (en)Anti-c5 antibodies and methods of use
EA035160B9 (en)Anti-st2 antibodies and use thereof
AU2012252153A8 (en)Anti-nerve growth factor antibodies and methods of preparing and using the same
MX2015005874A (en)Platelet-derived growth factor b specific antibodies and compositions and uses thereof.
MY161295A (en)Anti-nerve growth factor antibodies and methods of preparing and using the same
NZ629553A (en)Anti-big-endothelin-1 (big-et-1) antibodies and uses thereof
AU2015287227A8 (en)Immune-stimulating monoclonal antibodies against human interleukin-2
MX2017005642A (en)Anti-ang2 antibodies and methods of use.
MY196874A (en)Humanized anti-basigin antibodies and the use thereof
NZ702178A (en)Lingo-2 antagonists for treatment of conditions involving motor neurons
MX2016008520A (en)Novel anti-human bdca-2 antibody.
WO2020218951A3 (en)Monoclonal antibody that binds specifically to gitr
PH12017500722A1 (en)Antibodies that potently neutralize rabies virus and other lyssaviruses and uses thereof
MX2024000118A (en)Dna monoclonal antibodies targeting influenza virus.
MX2022003074A (en)Anti-cd371 antibodies and uses thereof.
JOP20200106A1 (en)Monoclonal antibody to il-5r?

Legal Events

DateCodeTitleDescription
MK9APatent expired
[8]ページ先頭
©2009-2025 Movatter.jp